Plomestane

Plomestane
Clinical data
Other names	MDL-18962; Propargylestrenedione; PED; 10-(2-Propyn-1-yl)estr-4-ene-3,17-dione; 10-Propargylestr-4-ene-3,17-dione
ATC code	None;
Identifiers
	IUPAC name 10H-(2-Propynyl)-estr-4-ene-3,17-dione;
CAS Number	77016-85-4;
PubChem CID	9904788;
ChemSpider	8080442;
UNII	FL3VS913TW;
CompTox Dashboard (EPA)	DTXSID601318490 ;
Chemical and physical data
Formula	C21H26O2
Molar mass	310.437 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4\C=C3/[C@@](CC#C)([C@H]2CC[C@@]1(C(=O)CC[C@H]1[C@@H]2CC3)C)CC4;
	InChI InChI=1S/C21H26O2/c1-3-10-21-12-8-15(22)13-14(21)4-5-16-17-6-7-19(23)20(17,2)11-9-18(16)21/h1,13,16-18H,4-12H2,2H3/t16-,17-,18-,20-,21-/m0/s1; Key:JKPDEYAOCSQBSZ-OEUJLIAZSA-N;

Other namesMDL-18962; Propargylestrenedione; PED; 10-(2-Propyn-1-yl)estr-4-ene-3,17-dione; 10-Propargylestr-4-ene-3,17-dione

Plomestane (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code name MDL-18962; also known as propargylestrenedione, PED) is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer.^[1]^[2]^[3]^[4]^[5] It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration.^[5] However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.^[6]

In addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties.^[5]

See also